, Volume 92, Issue 1, pp 58–67 | Cite as

Effect of combined or separate administration of piracetam and choline on learning and memory in the rat

  • A. Ennaceur
  • J. Delacour
Original Investigations


Different groups of rats received combined or separate administration of different doses of piracetam (P1:100, P2:200, and P4:400 mg/kg) and choline (C1:100 and C2:200 mg/kg). Compared to control treatment, C1 significantly improved performance in a delayed alternation (DA) task, while P1, P2, P4 or P1C1 had no effect. Moreover, rats receiving P2C1 and P4C1 were significantly inferior in acquiring DA to rats receiving the vehicle or separate administration of P1, P2 or C1. The different treatments with combined or separate administration of P and C had no effect on spontaneous locomotor activity and two-way avoidance conditioning. In a recognition-task only groups C1 and P4 were able to discriminate between familiar and new objects. The combined or separate administration of P1 and C1 on NA, DA, DOPAC, 5-HT, 5-HIAA levels, CAT activity and choline uptake were measured in frontal cortex and hippocampus: the only significant effect was a 5-HT increase in the hippocampus of rats treated with C1.

Key words

Piracetam Choline Piracetam + choline Delayed alternation Two-way avoidance Object recognition 5-HT CAT Choline uptake Rat 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aggleton JP (1985) One-trial object recognition by rats. Q J Exp Psychol 37B:279–294Google Scholar
  2. Aggleton JP, Mishkin M (1983) Visual recognition impairment following medial thalamic lesions in monkeys. Neuropsychologia 21:189–197Google Scholar
  3. Aigner T, Mitchell S, Aggleton J, Delong M, Struble R, Price D, Mishkin M (1984) Effects of scopolamine and physostigmine on recognition memory in monkeys after ibotenic acid injections into the area of the nucleus basalis of Meynert. In: Wurtman RJ, Corkin SH, Crowden JH (eds), Alzheimer's disease: Advances in basic research and therapies. Center for brain sciences and metabolism charitable trust, p 429Google Scholar
  4. Atanackovic D, Simonic A, Roganovic J (1984) Influence of piracetam on active avoidance behaviour in rats. Acta Pharm Jugosl 34:139–142Google Scholar
  5. Bartus RT (1980) Cholinergic drug effect on memory and cognition in animals. In: Poon LW (ed) Aging in the 1980 s: Psychological issues. American Psychological Association, Washington, DC, pp 163–180Google Scholar
  6. Bartus RT, Johnson HR (1976) Short-term memory in the rhesus monkey: disruption from the anticholinergic scopolamine. Pharmacol Biochem Behav 5:39–46Google Scholar
  7. Bartus RT, Dean RL (1985) Developing and utilizing animal models in the search for an effective treatment for age-related memory disturbances. In: Gottfries CG (ed) Normal aging, Alzheimer's disease and senile dementia. University of Brussels Press, pp 231–267Google Scholar
  8. Bartus RT, Dean RL, Goas JA, Lippa AS (1980) Age-related changes in passive avoidance retention: Modulation by dietary choline. Science 209:301–303Google Scholar
  9. Bartus RT, Dean RL, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric dysfunction: jtA critical review. Science 217:408–417Google Scholar
  10. Bartus RT, Dean RL, Beer B (1984) Cholinergic precursor therapy for geriatric cognition: its past, its present and a question of its future. In: Ordy JM, Harman D, Alfin-Slater R (eds) Nutrition in gerontology. Raven, New York, pp 191–225Google Scholar
  11. Bartus RT, Dean RL, Sherman KA, Friedman E, Beer B (1981) Profound effects of combining choline and piracetam on memory enhancement and cholinergic function in aged rats. Neurobiol Aging 2:105–111Google Scholar
  12. Beninger RJ, Tighe SA, Jhamandas K (1984) Effects of chronic manipulations of dietary choline on locomotor activity, discrimination learning and cortical acetylcholine release in aging adult Fisher 344 rats. Neurobiol Aging 5:29–34Google Scholar
  13. Beninger RJ, Jhamandas K, Boegman RJ, El-Defrawy SR (1986) Effects of scopolamine and unilateral lesions of the basal forebrain on T-maze spatial discrimination and alternation in rats. Pharmacol Biochem Behav 24:1353–1360Google Scholar
  14. Bierkamper GG, Goldberg AM (1980) Release of acetylcholine from the vascular perfused rat phrenic nerve-hemidiaphragm. Brain Res 202:234–237Google Scholar
  15. Brito GNO, Thomas GJ (1981) T-maze alternation, response patterning and septo-hippocampal circuitry in rats. Behav Brain Res 3:319–340Google Scholar
  16. Brito GNO, Davis BJ, Stopp LC, Stanton ME (1983) Memory and the septo-hippocampal cholinergic system in the rat. Psychopharmacology 81:315–320Google Scholar
  17. Brunello N, Cheney DL, Costa E (1982) Increase in exogenous choline fails to elevate the content or turnover rate of cortical, striatal or hippocampal acetylcholine. J Neurochem 38:1160–1163Google Scholar
  18. Buresova O, Bures J (1982) Radial-maze as a tool for assessing the effect of drugs on the working memory of rats. Psychopharmacology 77:268–271Google Scholar
  19. Buxton DA, Brimblecombe RW, French MC, Redfern PH (1976) Brain acetylcholine concentration and acetylcholinesterase activity in selectively-bred strains of rats. Psychopharmacology 47:97–99Google Scholar
  20. Cherkin A, Flood JF (1983) Remarkable potentiation among memory-enhancing cholinergic drugs in mice. In Intervention in the aging process, Part A: quantitation, epidemiology and clinical research. Liss, New York, pp 225–245Google Scholar
  21. Crook TH (1985) Clinical drug trials in Alzheimer's diseases. Ann NY Acad Sci 444:428–436Google Scholar
  22. Cumin R, Bandle EF, Gamzu E, Haefley WF (1982) Effects of the novel compound Aniracetam (Ro 13–5057) upon impaired learning in rodents. Psychopharmacology 78:104–111Google Scholar
  23. Delacour J (1977) Role of temporal lobe structures in visual short-term memory, using a new test. Neuropsychologia 15:681–684Google Scholar
  24. Delacour J, Coulon JF, David JC, Guenaire C (1983) Brain actopamine and strain differences in avoidance behavior. Brain Res 288:169–176Google Scholar
  25. Driscoll P, Dedeck J, Martin JR, Zivkovic B (1983) Two-way avoidance and acute shock stress induced alterations of regional noradrenergic dopaminergic and serotonergic activity in Roman high- and low-avoidance rats. Life Sci 33:1719–1725Google Scholar
  26. Ferris SH, Sathananthan G, Reisberg B, Gershon S (1979) Long-term choline treatment of memory-impaired elderly. Science 205:1039–1040Google Scholar
  27. Ferris SH, Reisberg B, Crook T, Friedman E, Schneck MK, Mir P, Sherman KA, Corwin J, Gershon S, Bartus RT (1982) Pharmacologic treatment of senile dementia: choline, l-dopa, piracetam and choline plus piracetam. Aging 19:475–481Google Scholar
  28. Flentge F, Van den Berg CJ (1979) Choline administration and acetylcholine in brain. J Neurochem 32:1331Google Scholar
  29. Flood JF, Smith GE, Cherkin A (1985) Memory enhancement: Supra-additive effect of subcutaneous cholinergic drug combinations in mice. Psychopharmacology 86:61–67Google Scholar
  30. Friedman E, Sherman KA, Ferris SH, Reisberg B, Bartus RT, Schneck MK (1981) Clinical response to choline plus piracetam in senile dementia: Relation to red-cell choline level. New Engl J Med 304:1490–1491Google Scholar
  31. Gaffan D, Saunders RC (1985) Running recognition of configural stimuli by fornix transected monkeys. Q J Exp Psychol 37B:61–71Google Scholar
  32. Gaffan D, Gaffan EA, Harrison S (1984) Effects of fornix transection on spontaneous and trained non-matching by monkeys. Q J Exp Psychol 36B:285–303Google Scholar
  33. Gamzu E (1985) Animal behavioral models in the discovery of compounds to treat memory dysfunction. Ann NY Acad Sci 444:370–393Google Scholar
  34. Giurgea EC, Salama M (1977) Nootropic drugs. Prog Neuropsychopharmacol 1:235–247Google Scholar
  35. Giurgea EC, Greindel MG, Preat S, Puigdevall J (1982a) Piracetam compensation of MAM-induced behavioral deficit in rats. Aging 19:281–286Google Scholar
  36. Giurgea EC, Greindl MG, Preat S (1982b) Cholinergic experimental modulation and learning. Abstr E.B.B.S., 2–4 Sept. 1982, Parma, Annual Gen MeetingGoogle Scholar
  37. Goodnick P, Gershon S (1984) Chemotherapy of cognitive disorders in geriatric subjects. J Clin Psychiatry 45:196–209Google Scholar
  38. Growdon JH, Corkin S, Huff FJ (1985) Clinical evaluation of compounds for the treatment of memory dysfunction. Ann NY Acad Sci 444:437–444Google Scholar
  39. Guenaire C, Delacour J (1985) Differential acquisition of a “Working memory” task by the Roman strains of rats. Physiol Behav 34:705–707Google Scholar
  40. Hepler DJ, Olton DS, Wenk GL, Coyle JT (1985a) Lesions in nucleus basalis magnocellularis and medial septal area of rats produce similar memory impairments. J Neurosci 5:866–873Google Scholar
  41. Hepler DJ, Wenk GL, Cribbs BL, Olton DS, Coyle JT (1985b) Memory impairments following basal forebrain lesions. Brain Res 346:8–14Google Scholar
  42. Hershkowitz M, Heron D, Samuel D, Shinitzky M (1982) The modulation of protein phosphorylation and receptor binding in synaptic membranes by changes in lipid fluidity: implications for ageing. Prog Brain Res 56:419–434Google Scholar
  43. Johns CA, Greenwald BS, Mohs RC, Davis KL (1983) The cholinergic treatment strategy in aging and senile dementia. Psychopharmacol Bull 19:185–197Google Scholar
  44. Kazdova E, Bohac O, Dolezal V, Faber J, Slanska J, Tucek S (1984) Treatment of dementia with high doses of lecithin and piracetam. Activ Nerv Super (Praha) 26:244–245Google Scholar
  45. Ladinsky H, Consolo S, Peri G, Crunelli Y, Samanin R (1977) Pharmacological evidence for a serotonergic-cholinergic link in the stratum. In: Jenden DJ (ed) Cholinergic mechanisms and psychopharmacology. Vol 24: Advances in behavioral biology, Plenum, New York, p 615Google Scholar
  46. Ladinsky H, Consolo S, Pugnetti P (1979) A possible central muscarinic receptor agonist role for choline in increasing rat striatal acetylcholine content. In: Barbeau A, Growdon JH, Wurtman J (eds) Nutrition and the brain, Vol 5: Choline and lecithin in brain disorders. Raven, New York, pp 227–232Google Scholar
  47. Martin JR, Driscoll P, Gentsch C (1984) Differential response to cholinergic stimulation in psychogenetically selected rat lines. Psychopharmacology 83:262–267Google Scholar
  48. Means LW, Franklin RD, Cliett CE (1980) Failure of piracetam to facilitate acquisition or retention in younger or older rats. Exp Aging Res 6:175–180Google Scholar
  49. Mervis RF, Bartus RT (1981) Modulation of pyramidal cell dendrite spine population in aging mouse neocortex: role of dietary choline. J Neuropathol Exp Neurol 68:412–419Google Scholar
  50. Millington WR, Goldberg AM (1982) Precursor dependence of acetylcholine release from rat brain in vitro. Brain Res 243:263–270Google Scholar
  51. Mishkin M, Delacour J (1975) An analysis of short-term visual memory in the monkey. J Exp Psychol: Animal Behav Proc 1:326–334Google Scholar
  52. Mohs RC, Davis KL, Tinklenberg JR, Hollister LE, Yesavage JA, Kopell BS (1979) Choline chloride treatment defects in the elderly. Am J Psychiatry 136:1275–1277Google Scholar
  53. Mohs RC, Davis KL, Tinklenberg JR, Hollister LE (1980) Choline chloride effects on memory in the elderly. Neurobiol Aging 1:21–25Google Scholar
  54. Muma NA, Rowell PP (1984) Behavioral effects of long-term choline and lecithin treatment in aged mice. IRCS Med Sci 12:1090–1091Google Scholar
  55. Nicolaus BJR (1982) Chemistry and pharmacology of nootropics. Drug Dev Res 2:463–474Google Scholar
  56. Ögren SO, Carlsson S, Bartfai T (1985) Serotonergic potentiation of muscarinic agonist evoked tremor and salivation in rat and mouse. Psychopharmacology 86:258–264Google Scholar
  57. Oglesby MW, Winter JC (1974) Strychnine sulfate and piracetam: lack of effect on learning in the rat. Psychopharmacologia 36:163–173Google Scholar
  58. Olton DS (1983) Memory functions and the hippocampus. In: Seifert W (ed) Neurobiology of the hippocampus. Academic, New York, p 335–373Google Scholar
  59. Olton DS, Becker JT, Handelmann GE (1979) Hippocampus, space and memory. Behav Brain Res 2:313–322Google Scholar
  60. Palacios JM, Kuhar MJ (1979) Choline: binding studies provide some evidence for a weak, direct agonist action in brain. Mol Pharmacol 16:1084–1088Google Scholar
  61. Pedata F, Moroni F, Banfi S, Pepeu G (1985) Effects of nootropic agents on brain cholinergic mechanisms: Clin Neuropharmacol 7:772–773Google Scholar
  62. Platel A, Jalfre M, Pawelec C, Roux S, Porsolt R (1984) Habituation of exploration activity in mice: effects of combination of piracetam and choline on memory processes. Pharmacol Biochem Behav 21:209–212Google Scholar
  63. Pomara N, Block R, Moore N, Rhiew HB, Berchou R, Stanley M, Gershon S (1984) Combined piracetam and cholinergic precursor treatment for primary degenerative dementia. IRCS Med Sci 12:388–389Google Scholar
  64. Pontecorvo MJ, Evans HL (1985) Effects of aniracetam on delayed matching-to-sample performance of monkeys and pigeons. Pharmacol Biochem Behav 22:745–752Google Scholar
  65. Poschel BPH, Mariott JG, Gluckman MI (1983) Pharmacology of the cognition activator Pramiracetam (C1–879). Drugs Exp Clin Res 9:853–871Google Scholar
  66. Pugsley TA, Poschel BPH, Downs DA, Shih Y-H, Gluckman MI (1983) Some pharmacological and neurochemical properties of a new cognition activator agent, Pramiracetam (C1–879). Psychopharmacol Bull 19:721–726Google Scholar
  67. Reisberg B, Ferris SH, Schneck MK, Corwin J, Mir P, Friedman E, Sherman KA, McCarthy M, Bartus RT (1982) Piracetam in the treatment of cognitive impairment in the elderly. Drug Dev Res 2:475–480Google Scholar
  68. Ridley RM, Murray TK, Johnson JA, Baker HF (1986) Learning and memory impairment following lesion of the basal nucleus of Meynert in the marmoset: modification by cholinergic drugs. Brain Res 376:108–116Google Scholar
  69. Ridley RM, Bowes PM, Baker HF, Crow TJ (1984) An involvement of acetylcholine in object discrimination learning and memory in the marmoset. Neuropsychologia 22:253–263Google Scholar
  70. Robinson SE (1983) Effect of specific serotonergic lesions on cholinergic neurons in the hippocampus, cortex and striatum. Life Sci 32:345–353Google Scholar
  71. Samanin R, Quattrone A, Peri G, Ladinsky H, Consolo S (1978) Evidence of an interaction between serotonergic and cholinergic neurons in the corpus striatum and hippocampus of the rat brain. Brain Res 151:73–82Google Scholar
  72. Sara SJ, David-Remacle M (1974) Recovery from electroconvulsive shock-induced amnesia by exposure to the training environment: Pharmacological enhancement by piracetam. Psychopharmacologia 36:59–66Google Scholar
  73. Schindler U, Rush DK, Fielding S (1984) Nootropic drugs: Animal models for studying effects on cognition. Drug Dev Res 4:567–576Google Scholar
  74. Schneck MK (1983) Nootropics. In: Reisberg B (ed) Alzheimer's diseases. Free, New YorkGoogle Scholar
  75. Serby M, Corwin J, Rostrosen J, Ferris SH, Reisberg B, Friedman E, Sherman KA, Jordan B, Bartus RT (1983) Lecithin and piracetam in Alzheimer's disease. Psychopharmacol Bull 19:126–129Google Scholar
  76. Speth RC, Yamamura HI (1979) On the ability of choline and its analogues to interact with muscarinic cholinergic receptors in the rat brain. Eur J Pharmacol 58:197Google Scholar
  77. Thal LJ, Rosen WG, Sharpless NS, Crystal HA (1981) Choline chloride fails to improve cognition in Alzheimer's disease. Neurobiol Aging 2:205–208Google Scholar
  78. Valzelli L, Bernasconi S, Sala A (1980) Piracetam activity may differ according to the age of the recipient mouse. Int Pharmacopsychiatr 15:150–156Google Scholar
  79. Vincent G, Velderese A, Gamzu E (1984) The effects of Aniracetam (Ro 13–5057) and piracetam on the enhancement of memory in mice. Soc Neurosci Abstr 10:258Google Scholar
  80. Wecker L (1986) Neurochemical effects of choline supplementation. Can J Physiol Pharmacol 64:329–333Google Scholar
  81. Winer BJ (1971) Statistical principles in experimental design. McGraw Hill, New YorkGoogle Scholar
  82. Woelk H (1979a) Effect of piracetam on the incorporation of 32P into phospholipid of neural and glial cells isolated from rabbit cerebral cortex. Pharmacopsychiatry 12:251–256Google Scholar
  83. Woelk H (1979b) On the influence of piracetam upon neuronal and synaptosomal phospholipase A activity. Arzneimittelforschung 29:615–618Google Scholar
  84. Woelk H, Peiler-Ishikawa K (1978) The action of piracetam on the formation of ethanolamine plasmogen by neuronal microsomes of the developing rat brain. Arzneimittelforschung 28:1752–1756Google Scholar
  85. Wolthuis OL (1971) Experiments with UCB 6215, a drug which enhances acquisition in rats: its effects compared with those of methamphetamine. Eur J Pharmacol 16:283–297Google Scholar
  86. Wurtman RJ, Magil SG, Reinstein DK (1981) Piracetam diminishes hippocampal acetylcholine levels in rats. Life Sci 28:812–814Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • A. Ennaceur
    • 1
  • J. Delacour
    • 1
  1. 1.Laboratoire de PsychophysiologieUniversité Paris VIIParis Cedex 05France

Personalised recommendations